Explore capabilities →

Capability · Expert Litigation Intelligence

Win the Rule 702 hearing before it starts.

Every expert on both sides, how courts have ruled on them, and a sourced cross-examination outline — in minutes instead of days. Across medicine, engineering, finance, environmental science and academia.

195 Experts profiled
100%Findings backed by evidence
MinutesTo a usable dossier
68Opinions read
Scroll

Use cases

23 questions Expert Litigation answers.

Real questions from the teams that use it, answered with live data.

Mass-tort teams preparing for expert discovery

What is the newest science on GLP-1 drugs?

12 recent papers whose own title names the subject, newest first. Titles and journals only.

  1. GLP-1 receptor agonists and ocular safety- Pharmacokinetic insights into ischemic optic neuropathy and diabetic retinopathy risk: A review.Biomolecules & biomedicine · 2026 Sep 7
  2. Indication-specific adverse event profiles of semaglutide and liraglutide: a FAERS disproportionality analysis.Frontiers in pharmacology · 2026 Sep 29
  3. [Non-arteritic anterior ischemic optic neuropathy associated with tirzepatide (Mounjaro®): A case report documented by multimodal imaging].Journal francais d'ophtalmologie · 2026 Sep 29
  4. Non-Arteritic Anterior Ischaemic Optic Neuropathy Associated with Semaglutide use.Irish medical journal · 2026 Sep 28
  5. GLP-1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications.Journal of internal medicine · 2026 Oct 9
See the literature →

Mass-tort teams preparing for expert discovery

What is the newest science on hair straighteners?

11 recent papers whose own title names the subject, newest first. Titles and journals only.

  1. Use of hair relaxers and hair dyes during pregnancy and breast tissue composition in mothers and adolescent daughters.Breast cancer research : BCR · 2026 Jul 29
  2. Use of hair straighteners and chemical relaxers and incidence of non-reproductive cancers.Journal of the National Cancer Institute · 2026 Jan 1
  3. Systematic Review of the Epidemiology of Hair Relaxer Use and Hormone-Sensitive Reproductive Outcomes Among Black Adult Women in the United States.Journal of applied toxicology : JAT · 2025 Jan 19
  4. A systematic review of association between use of hair products and benign and malignant gynecological conditions.European journal of obstetrics, gynecology, and reproductive biology · 2024 Feb 14
  5. Hair relaxer use and risk of uterine cancer in the Black Women's Health Study.Environmental research · 2023 Oct 10
See the literature →

Mass-tort teams preparing for expert discovery

What is the newest science on talc?

12 recent papers whose own title names the subject, newest first. Titles and journals only.

  1. Talc Use and Risk of Cancer: An Umbrella Review and Overlapped Analysis.Cancer reports (Hoboken, N.J.) · 2026 Oct
  2. Personal Talc Use and Incident Lung Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026 Nov 2
  3. Safety and Efficacy of Single-Stage Synchronous Bilateral VATS Talc Poudrage for Malignant Pleural Effusion.Cancers · 2026 May 22
  4. Talc Exposure and Risk of Ovarian Cancer: A Systematic Review and Meta-Analysis with Limited Evidence on Cervical and Endometrial Cancers.Cancers · 2026 May 13
  5. Development and validation of a predictive model for pleural effusion control following talc pleurodesis in malignant pleural effusion.International journal of clinical oncology · 2026 Mar 17
See the literature →

Mass-tort teams preparing for expert discovery

What is the newest science on social media and adolescents?

12 recent papers whose own title names the subject, newest first. Titles and journals only.

  1. "This didn't exist back then": A focus group study on adolescents' account of mental illness perceptions in the context of family, peers, and social media.Social science & medicine (1982) · 2026 Sep 4
  2. Problematic Social Media Use and Depressive and Anxiety Symptoms in Adolescents.Pediatrics · 2026 Nov 1
  3. Associated Factors of Problematic Social Media Use, Cyberbullying, and Cybervictimization Among Adolescents: A Cross-Sectional Study.Journal of child and adolescent psychiatric nursing : official publication of the Association of Child and Adolescent Psychiatric Nurses, Inc · 2026 Nov
  4. "With all your friends in your pocket" - a qualitative study about adolescents' experiences with social media from a health-promoting perspective.International journal of qualitative studies on health and well-being · 2026 Mar 6
  5. Mapping mental health and suicide-related discourse on TikTok: An AI-based social media listening study.Journal of affective disorders · 2026 Jun 15
See the literature →

Drug and device litigators

Which pharmaceutical experts have courts already ruled on?

3 of the 195 experts work in pharmaceutical; 0 had testimony excluded or limited at least once.

  1. Daniel L. Raines1 opinion · United States District Court for the Eastern District of Pennsylvania
  2. Eliot L. Siegel1 opinion · United States District Court for the Eastern District of Pennsylvania
  3. Linda Nguyen1 opinion · United States District Court for the Eastern District of Pennsylvania
See the pharmaceutical experts →

Securities and commercial litigators

Which finance and economics experts have courts already ruled on?

20 of the 195 experts work in finance and economics; 2 had testimony excluded or limited at least once.

  1. Bala Dharan1 opinion · District Court, District of Columbia
  2. Monica Noether1 opinion · Court of Appeals for the Seventh Circuit
  3. Bruce Silverman1 opinion · Court of Appeals for the Ninth Circuit
  4. Carol Scott1 opinion · Court of Appeals for the Ninth Circuit
  5. Catherine Grello1 opinion · Court of Appeals of Tennessee
See the finance and economics experts →

Employment litigators

Which employment experts have courts already ruled on?

11 of the 195 experts work in employment; 1 had testimony excluded or limited at least once.

  1. Anthony G. Greenwald1 opinion · Court of Appeals for the Third Circuit
  2. Charles Mann1 opinion · District Court, District of Columbia
  3. Frank Chaloupka1 opinion · District Court, District of Columbia
  4. James Spaeth1 opinion · District Court, District of Columbia
  5. John Johnson1 opinion · Court of Appeals for the Ninth Circuit
See the employment experts →

Construction and product-defect teams

Which engineering experts have courts already ruled on?

23 of the 195 experts work in engineering; 5 had testimony excluded or limited at least once.

  1. David Johnson1 opinion · Court of Appeals of Tennessee
  2. Donald E. Sommer1 opinion · Superior Court of Delaware
  3. Glenn Akhavein1 opinion · Court of Appeals for the Ninth Circuit
  4. Mari S. Truman1 opinion · Court of Appeals for the Eighth Circuit
  5. William Muzzy1 opinion · Superior Court of Delaware
See the engineering experts →

Trial teams vetting an opposing expert

Has a court excluded this expert's testimony before?

17 of the 195 experts in the directory have at least one ruling that excluded or limited their testimony, and 19 have rulings admitting it. Each ruling is shown with the passage that names the expert.

  1. Anthony G. GreenwaldRudolph Karlo v. Pittsburgh Glass Works LLC · Court of Appeals for the Third Circuit, 2017
  2. Bala DharanIn Re: Fannie mae/freddie Mac Senior Preferred Stock Purchase Agreement Class Action Litigations · District Court, District of Columbia, 2022
  3. Brent D. KergerConstantine, K. v. Lenox Instr. Co. · Superior Court of Pennsylvania, 2024
  4. Cyril H. WechtCommonwealth v. Yocolano · Superior Court of Pennsylvania, 2017
  5. David JohnsonRuth Mitchell v. City of Franklin, Tennessee · Court of Appeals of Tennessee, 2024
Search every expert →

Environmental and toxic-tort teams

Which experts testify in environmental cases?

18 of the 195 experts appear in environmental cases. Each one's record shows the case, the court and how the court treated the testimony.

  1. Andrew SchneiderEngilis v. Monsanto Company
  2. Anna SomiglianaOccupational and environmental lung diseases, Occupational Health and Global Justice · Northrop Grumman Systems Corp., Etc. v. Britt
  3. Brooke Taylor MossmanOccupational and environmental lung diseases, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis · Bader v. Johnson & Johnson
  4. Cyril H. WechtAutopsy Techniques and Outcomes, Historical and Scientific Studies · Commonwealth v. Yocolano
  5. Ethan A. NatelsonAndrews v. United States Steel Corp.
See every environmental expert →

Counsel checking an expert for industry ties

Has this expert received payments from industry?

12 of the 195 experts are physicians with industry payments on public record, matched by provider registry number rather than by name alone.

  1. Anil Vachani$10K in 2025, mostly from INTUITIVE SURGICAL, INC.
  2. Nizar Souayah$9K in 2025, mostly from Takeda Pharmaceuticals U.S.A., Inc.
  3. George Wandling$9K in 2025, mostly from Glaukos Corporation
  4. Suber Huang$6K in 2025, mostly from Alcon Vision LLC
  5. Noelle Cloven$5K in 2025, mostly from Genmab U.S., Inc.
Open an expert's dossier →

Teams weighing an expert's standing in the field

Whose published research carries the most weight?

39 of the 195 experts have a publication record confirmed as theirs: the research field matches the case, so a namesake's papers are not counted.

  1. James Crapoh-index 116 · 692 papers · National Jewish Health
  2. David Franzh-index 57 · 183 papers · University of Rome Tor Vergata
  3. Anil Vachanih-index 56 · 442 papers · University of Pennsylvania
  4. Brian Chaseh-index 49 · 298 papers · Centre National de la Recherche Scientifique
  5. Eliot L. Siegelh-index 47 · 303 papers · University of Maryland Baltimore
Search every expert →

Teams tracking the science behind a claim

Who is running clinical studies on PFAS?

30 PFAS clinical studies, led by 24 organisations.

  1. Hospices Civils de LyonDo Endocrine Disruptors Accumulate in Children Undergoing Paediatric Dialysis?
  2. University of California, San FranciscoExamining a Novel Gastrointestinal Intervention to Negate Environmental Toxicants (ENGINE)
  3. Cambiotics ApSEffect of a Dietary Supplement Versus Placebo on Serum PFAS Levels in Male Firefighters
  4. Emory UniversityPFAS Clinical Trial
  5. Institut National de la Santé Et de la Recherche Médicale, FranceExposure to Persistent Organic Pollutants and Severity of Endometriosis in the ComPaRe-Endometriosis Cohort
See every trial →

Experts and counsel keeping up with the literature

What is the newest research on ethylene oxide?

1,035 published papers on ethylene oxide. The newest are below, with titles and journals only.

  1. Molecular dosimetry of hemoglobin adducts in mice exposed to ethylene oxide.Archives of toxicology · 2026 Jul 1
  2. Rheological dataset of calcium-alginate hydrogels after ultraviolet, ethylene oxide, steam, gamma, and high hydrostatic pressure treatments.Data in brief · 2026 Oct 13
  3. Regarding ethylene exposure and endogenous ethylene oxide levels in humans (Lin et al., 2025).Journal of exposure science & environmental epidemiology · 2026 Sep 5
  4. A risk assessment of ethylene oxide release from a sterilization facility into a community.Journal of the Air & Waste Management Association (1995) · 2026 Apr 30
  5. Molecular dosimetry of DNA adducts in mice exposed to ethylene oxide.Toxicological sciences : an official journal of the Society of Toxicology · 2026 Jul 1
See the literature →

Patent and IP litigators

Which experts testify in patent and IP cases, and how did courts treat them?

14 of the 195 experts appear in IP cases.

  1. Arnold BrodySusan Elaine Bostic, Individually and as Personal Representative of the Heirs and Estate of Timothy Shawn Bostic, Helen Donnahoe And Kyle Anthony Bostic v. Georgia-Pacific Corporation · Texas Supreme Court
  2. Carlos BustamanteDr. Ruthie Harper and PLLG, LLC v. Wellbeing Genomics Pty Ltd. · Texas Court of Appeals, 3rd District (Austin)
  3. Kenneth BritzSturdza v. United Arab Emirates · District Court, District of Columbia
  4. Kenneth MillsDr. Ruthie Harper and PLLG, LLC v. Wellbeing Genomics Pty Ltd. · Texas Court of Appeals, 3rd District (Austin)
  5. Mark KeeganBillfloat Inc. v. Collins Cash Inc. · Court of Appeals for the Ninth Circuit
See every IP expert →

Securities, valuation and damages teams

Who testifies on damages, valuation and securities?

20 of the 195 experts appear in finance cases; 2 have had testimony excluded or limited.

  1. Bala DharanIn Re: Fannie mae/freddie Mac Senior Preferred Stock Purchase Agreement Class Action Litigations · District Court, District of Columbia · excluded or limited
  2. Monica NoetherMessner v. Northshore University HealthSystem · Court of Appeals for the Seventh Circuit · excluded or limited
  3. Bruce SilvermanJustin Lytle v. Nutramax Laboratories, Inc. · Court of Appeals for the Ninth Circuit
  4. Carol ScottJustin Lytle v. Nutramax Laboratories, Inc. · Court of Appeals for the Ninth Circuit
  5. Catherine GrelloEdna Gergel v. James Gergel · Court of Appeals of Tennessee
See every finance expert →

Construction, product and engineering disputes

Which engineering experts appear in court, and in which cases?

23 of the 195 experts appear in engineering cases; 5 have had testimony excluded or limited.

  1. David JohnsonRuth Mitchell v. City of Franklin, Tennessee · Court of Appeals of Tennessee · excluded or limited
  2. Donald E. SommerLaugelle v. Bell Helicopter Textron Inc. · Superior Court of Delaware · excluded or limited
  3. Glenn AkhaveinPhyllis Grodzitsky v. American Honda Motor Co., Inc. · Court of Appeals for the Ninth Circuit · excluded or limited
  4. Mari S. TrumanJulie Sprafka v. Medical Device Bus. Services · Court of Appeals for the Eighth Circuit · excluded or limited
  5. William MuzzyLaugelle v. Bell Helicopter Textron Inc. · Superior Court of Delaware · excluded or limited
See every engineering expert →

Employment and labor counsel

Which experts testify in employment cases?

11 of the 195 experts appear in employment cases; 1 have had testimony excluded or limited.

  1. Anthony G. GreenwaldRudolph Karlo v. Pittsburgh Glass Works LLC · Court of Appeals for the Third Circuit · excluded or limited
  2. Charles MannMoore v. Napolitano · District Court, District of Columbia
  3. Frank ChaloupkaUnited States v. Philip Morris USA · District Court, District of Columbia
  4. James SpaethUnited States v. Philip Morris USA · District Court, District of Columbia
  5. John JohnsonOlean Wholesale Grocery Co-Op v. Bumble Bee Foods LLC · Court of Appeals for the Ninth Circuit
See every employment expert →

The premise

In mass torts, cases live or die at the gate.

In mass torts and complex commercial cases alike, cases live or die at the Rule 702 hearing. Uncommon Context shows where each expert is vulnerable, from the public record, before the other side finds it. Every finding is backed by the court record, and anything unverified is hidden, so a first draft is something a partner can rely on.

For plaintiffs

Stress-test your own experts before disclosure, so no one gets excluded by surprise.

For defense

Find the weak points in opposing experts in minutes.

For both

Every claim is checkable, which matters when it ends up in a brief.

The database

195 experts, every one named in a real opinion.

Search by name, institution, court or field — then open a full dossier with the court’s own words, the Rule 702 outcome, publications and links to verify identity. No account required.

What a dossier looks like

A real example, built from the record.

Built from the court’s August 15, 2025 ruling on GLP-1 gastrointestinal injury testimony. This is the layout every dossier in the directory uses — exposure, numbered exhibits, then questions tied to them.

uncommon-context.vercel.app / experts / daniel-l-raines
DR
Dr. Daniel L. Raines

Chief of Gastroenterology, LSU Health Sciences Center · Plaintiffs’ expert

Moderate exposure on the public record

LowModerateHigh

Computed from the exhibits below, not typed by hand: 1 ruling excluding this expert. Every dossier shows this read, and says plainly when no adverse ruling was found.

DX-1 · Excluded

In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation (E.D. Pa., Aug 15 2025)

Record: the court excluded his opinion that gastroparesis can be diagnosed without a gastric emptying study, finding the method unreliable under Rule 702.

Open the ruling ↗

Exhibits are numbered per expert and each one links to the opinion it was quoted from. Where the record holds nothing adverse, the dossier says so instead of padding the list.

Cross-examination outline

Every question rests on a numbered exhibit DX-1

Q 1Your testimony was excluded in In re: Glucagon-Like Peptide-1 Receptor Agonists in 2025 — correct?

Each question restates a fact already quoted in an exhibit and asks the witness to confirm it. Nothing is characterised, and no motive is asserted.

What makes it different

A name search that answers with the record.

01

Search any expert across 43 courts

Type a name, field, institution or court. Every hit opens a dossier built from the opinions that named that person — state and federal, trial and appellate.

02

Every finding is an exhibit you can open

Each item links to the page it came from. Anything the research couldn’t source is marked unconfirmed and hidden.

03

It checks the report against the expert’s own record

Paste the report’s opinions and Uncommon Context compares each one to the expert’s publications, guidelines, and prior testimony.

04

It shows how it knows it’s the same person

Common names get flagged with the evidence behind each match, so you don’t cross-examine the wrong Dr. Smith.

Across every practice area

Ten fields, each with its own identity anchor.

Medicine came first, where a national provider number identifies a person exactly. Other disciplines need different anchors — and where no registry exists, a name match is a lead, never a finding.

Hard anchor

Medicine (NPI), academia (ORCID), finance (CRD). A registry number resolves to one person, so findings can be stated plainly.

Medium anchor

Engineering and environmental science. Strong identifiers exist but need one corroborating fact before the dossier asserts a match.

Weak anchor

Regulatory and standards practice. Two independent facts must agree, or the finding goes to a human reviewer.

How Uncommon Context compares

Four ways to vet an expert.

Litigators vet experts today by ordering research reports, searching legal databases, or asking a general AI assistant. Here’s how Uncommon Context differs from each.

Uncommon ContextOrdered research reportsLegal research databasesGeneral AI assistants
Where you startSearch any name, field or court. Both sides’ experts surface the same way.Order a report on one expert.Search one name at a time.Type a question into a chat window.
Time to a usable answerMinutes.Typically days.Minutes, but you assemble the picture yourself.Seconds, but you still have to check it.
Organized aroundThe expert, the opinions naming them, and how each court ruled.A single expert.A single expert, case, or judge.Whatever you asked.
How an expert gets listedA court opinion named them in an expert role. Listing cannot be bought.You commission the research.Appears if named in an indexed document.Whatever the model recalls.
SourcesEvery finding links to the page it came from. Anything unsourced is hidden.Compiled by a researcher and cited in the report.Documents inside the database.Citations can be missing or wrong.
Report versus the expert’s own recordEach opinion is compared to the expert’s publications, guidelines, and prior testimony.Depends on the researcher and the order.You do the comparison.Only covers what you paste in.
Is this the right person?Shows the evidence behind every match and flags common names.Rarely shown.Rarely shown.Not shown.
What’s missingLabeled plainly: “Docket only” and “Unconfirmed.”Not usually stated.Not usually stated.Not stated.

Compares typical approaches, not specific vendors. Features vary by provider and plan.

195 experts · 43 courts

Search any expert, in any court.

Every name here was pulled from a published opinion that names them in an expert role — state trial courts, state appellate courts, federal district and circuit courts, and the Court of Federal Claims. Not a curated shortlist, and not a paid directory.

Named in the record

Each expert enters only when an opinion names them as a testifying or retained expert. The sentence that did it is stored and shown as the evidence.

How each court ruled

Where a Rule 702 motion was decided, the dossier records whether the testimony was excluded or admitted — and stays silent where the opinion never ruled.

No pay-to-list

Marketing directories charge an expert several hundred dollars a year to appear. Nothing here can be bought; the only way in is a court opinion.

Search the directory →

Search runs entirely in your browser. No account, and no record of what you looked for.

Clinical trials

Trials on the drugs and exposures these experts testify about.

Studies of GLP-1 drugs, opioid use disorder, concussion, PFAS, benzene, asbestos and air pollution, with the organisation sponsoring each one.

208 clinical trials · updated November 2, 2026 · newest first

TrialSponsorStatusStarted
Supplementary Neuromuscular Rehabilitation During Acute Concussion RecoveryNorthern Illinois UniversityNot Yet Recruiting2027-08-02
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After TreatmentNational Cancer Institute (NCI)Recruiting2027-04-12
Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent ObesityNot Yet Recruiting2027-03
Semaglutide for Weight Management During Hormone Therapy for Early Breast CancerAarhus University HospitalNot Yet Recruiting2027-03
Opioid Reduction and Enhanced Recovery in Orthopaedic Surgery (OREOS)-KneeMcMaster UniversityNot Yet Recruiting2027-02-01
Pediatric Electrocutaneous Analgesia for Children Experiencing Neuropathic PainJohns Hopkins UniversityNot Yet Recruiting2027-01
Remote Intervention to Prevent OverdoseUniversity of Alabama at BirminghamNot Yet Recruiting2027-01
Semaglutide for the Treatment of Cannabis Use DisorderMassachusetts General HospitalNot Yet Recruiting2027-01-10
Suzetrigine (Journavx) as Multimodal Therapy for Pain Management in Adults Undergoing Surgery for Hip FractureBeth Israel Deaconess Medical CenterNot Yet Recruiting2027-01-05
Peer-led, Mobile App Supported Linkage to Opioid Use Disorder TreatmentJohns Hopkins UniversityNot Yet Recruiting2027-01-01
Sleep MAPP in the Polytrauma/TBI System of CareVA Office of Research and DevelopmentNot Yet Recruiting2027-01-01
Exposure to Persistent Organic Pollutants and Severity of Endometriosis in the ComPaRe-Endometriosis CohortInstitut National de la Santé Et de la Recherche Médicale, FranceNot Yet Recruiting2026-12
Prospective Twin Pregnancy Cohort at Montpellier University HospitalUniversity Hospital, MontpellierNot Yet Recruiting2026-12
PRP Versus NP Injections for Chronic Discogenic Low Back PainWalter Reed National Military Medical CenterNot Yet Recruiting2026-12
A Prospective Study of Cognitive Changes in Retired and Late-Career Professional Soccer PlayersUniversity Hospital, Strasbourg, FranceNot Yet Recruiting2026-12-02
Treating Seasonal Depression With DaylightNot Yet Recruiting2026-12-01
Allopregnanolone in Chronic Complex Traumatic Brain InjuryVA Office of Research and DevelopmentNot Yet Recruiting2026-12-01
PFAS Clinical TrialEmory UniversityNot Yet Recruiting2026-11
Low TGF-β and Embryo Implantation in the Context of Assisted Reproductive Technology: Confirmation of a Biomarker Predictive of Success and Characterization of the Immune Microenvironment.Centre Hospitalier Universitaire de NiceNot Yet Recruiting2026-11
Behavioral Optimization for Overcoming Suboptimal Treatment Retention (BUP-BOOSTeR)Boston UniversityNot Yet Recruiting2026-11
Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)Sunnybrook Health Sciences CentreRecruiting2026-11
The INTERvening for LUNG Health TrialJohns Hopkins UniversityNot Yet Recruiting2026-11-15
GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way ForwardUniversity of MinnesotaNot Yet Recruiting2026-11-15
A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001)Merck Sharp & Dohme LLCNot Yet Recruiting2026-11-13
SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNot Yet Recruiting2026-11-07
Measuring the Effects of Neurostimulation on Risky and Ambiguous Decision-Making Capacity in People With and Without Substance Use DisorderNational Institute on Drug Abuse (NIDA)Suspended2026-11-05
Development of an Interview-Informed Timeline Follow-Back (TLFB) for Opioid Use in the Era of FentanylNational Institute on Drug Abuse (NIDA)Enrolling By Invitation2026-11-05
Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy VolunteersNational Center for Complementary and Integrative Health (NCCIH)Not Yet Recruiting2026-11-05
Effect of Oxybutynin on Opioid Use After Urologic Surgery in ChildrenUniversity of CalgaryNot Yet Recruiting2026-11-01
Effectiveness of Pollution Monitoring in Clinical Exercise RehabilitationUniversity of LeicesterNot Yet Recruiting2026-10
Rehabilitation Through Virtual Immersion & Integrated Exposure for Mild Traumatic Brain Injury (ReVIVE for mTBI)Johns Hopkins UniversityRecruiting2026-10
Cognitive Effects of Hyperbaric Oxygen Therapy (HBOT) After a Traumatic Brain InjuryAssaf-Harofeh Medical CenterNot Yet Recruiting2026-10
Mechanisms of Weight Loss: Tirzepatide vs SemaglutideMcMaster UniversityRecruiting2026-10-31
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapyNovartis PharmaceuticalsNot Yet Recruiting2026-10-30
Translational Health Research Into Vascular and Neurocognitive Effects of Weight LossRecruiting2026-10-21
Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese ParticipantsShanghai JMT-Bio IncRecruiting2026-10-20
Metabolic Effects of Switching From Injectable Semaglutide to TirzepatideLMC Diabetes & Endocrinology LtdActive Not Recruiting2026-10-15
Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.McGill University Health Centre/Research Institute of the McGill University Health CentreRecruiting2026-10-13
A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in ChinaNovo Nordisk A/SRecruiting2026-10-12
Do Endocrine Disruptors Accumulate in Children Undergoing Paediatric Dialysis?Hospices Civils de LyonNot Yet Recruiting2026-10-10
Effect of a Dietary Supplement Versus Placebo on Serum PFAS Levels in Male FirefightersCambiotics ApSRecruiting2026-10-08
FutureShape FamilyRecruiting2026-10-01
Plastic Detox During IVF TreatmentNot Yet Recruiting2026-10-01
A Multiple-dose Study Investigating the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix in Healthy Adult SubjectsBasilea PharmaceuticaRecruiting2026-10-01
Effect of Remimazolam Versus Propofol Total Intravenous Anesthesia on Intraoperative Hemodynamic Stability in Patients Undergoing Thoracic or Abdominal Endovascular Aortic RepairSeoul National University HospitalRecruiting2026-10-01
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)Veterans Recovery Network IncNot Yet Recruiting2026-10-01
The PIONEER Comparative Effectiveness Study - Project 2University of MichiganNot Yet Recruiting2026-10-01
Postoperative Residual Neuromuscular Block and Passive Smoke Exposure in Pediatric Dental PatientsIstanbul University - CerrahpasaNot Yet Recruiting2026-09
Sustaining Health After an Intensive Weight-loss Pro-grammeCopenhagen University Hospital, HvidovreEnrolling By Invitation2026-09
Electroencephalography Markers of Brain Stimulation in Post-Concussion PatientsUniversity of LiegeNot Yet Recruiting2026-09
The CANadian EXAcerbation of COPD TrialMcGill University Health Centre/Research Institute of the McGill University Health CentreNot Yet Recruiting2026-09-28
Voices Illuminating Solutions for Outdoor Workers' Needs and SafetyStanford UniversityRecruiting2026-09-25
PLLA and CaHA-R for Aesthetic RejuvenationErevna Innovations IncRecruiting2026-09-21
Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With ObesityYuzuncu Yil UniversityRecruiting2026-09-15
Remimazolam Versus Propofol for Maintenance of Anaesthesia During Major Hepatectomy Under Low Central Venous PressureBeijing Tsinghua Chang Gung HospitalNot Yet Recruiting2026-08
Effect of an Antioxidant Dietary Supplement on Skin RadianceRobertet SAActive Not Recruiting2026-08-31
A Two-Way Path to Health: Environmental Influences on Skeletal Muscle Endocrine FunctionPoznan University of Physical EducationNot Yet Recruiting2026-08-20
Intradiscal Ozone/Oxygen Injection for Treatment of Contained Lumbar Disc HerniationBeam Research, IncEnrolling By Invitation2026-08-17
MediBeacon® Transdermal GFR System for the Evaluation of Kidney Function in Adults With Heart FailureRecruiting2026-08-10
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesNovo Nordisk A/SRecruiting2026-08-04
Rosuvastatin and Losartan Pharmacokinetics After Bariatric SurgeryHospital das Clínicas de Ribeirão PretoNot Yet Recruiting2026-08-02
EXercise-induced PhysioLogical Adaptations In Neurological DisordersBrigham and Women's HospitalRecruiting2026-07-22
Lateral QL Block vs Intrathecal Morphine for Cesarean SectionOndokuz Mayıs UniversityRecruiting2026-07-15
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusRecruiting2026-07-06
TRACK-TBI Precision Medicine Part 3 - Option IIUniversity of California, San FranciscoEnrolling By Invitation2026-07-02
Risk Factors of Atrial Fibrillation After Cardiac SurgeryCentre Hospitalier Régional Metz-ThionvilleNot Yet Recruiting2026-07-01
Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans StudyUniversity of Rhode IslandNot Yet Recruiting2026-07-01
Role of the Environment in Pediatric ObesityUniversity Hospital, ToursNot Yet Recruiting2026-06
Propofol-Only Versus Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance ImagingBoston Children's HospitalRecruiting2026-06-30
Evaluating DFPP for Microplastic and PFAS ReductionProxima Health, IncEnrolling By Invitation2026-06-12
Dexamethasone for Ureteral STent Symptoms (DUSTS)The Methodist Hospital Research InstituteRecruiting2026-06-10
Lungs on Fire: Wildfire Smoke, Incident Diseases, Susceptible Populations, and Community Values in CanadaUniversity of British ColumbiaRecruiting2026-05-26
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based TherapyBiomea Fusion IncRecruiting2026-04-30
Effect of Plant-based Diets on Liver Biomarkers, Cardiometabolic Health, and Exposure to Environmental Contaminants and Endocrine Disruptors in Patients With Metabolic Liver Disease.Not Yet Recruiting2026-04-18
THREAT: Testing Harms Related to Exposure to Allergenic and Epithelial ToxinsNational Institute of Allergy and Infectious Diseases (NIAID)Recruiting2026-04-15
A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial NeoplasiaUniversity of FloridaRecruiting2026-04-07
Impact of Parental Training in Endocrine Disruptors on the Excretion of Urinary Biomarkers in NewbornsHospices Civils de LyonRecruiting2026-03-16
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage MesotheliomaNational Cancer Institute (NCI)Withdrawn2026-03-16
Reliability of Standardized IQ Testing Under Modafinil, Racetam-Class Compounds, Sleep Restriction and Daily ActivityCompleted2026-03-09
Examining a Novel Gastrointestinal Intervention to Negate Environmental Toxicants (ENGINE)University of California, San FranciscoRecruiting2026-03-01
Ultrasound Examination of the VMO in Patellofemoral Pain SyndromeHasan Kalyoncu UniversityNot Yet Recruiting2026-02-25
Comparison of Talc Slurry Versus Talc Insufflation: A Study on Effectiveness, Safety, and Hospital Outcomes in PleurodesisUniversity of Health Sciences LahoreNot Yet Recruiting2026-02-01
Knee Osteoarthritis and Thermal Spa TreatmentCEN BiotechActive Not Recruiting2026-01-27
Reducing Gingival Pigmentation Through Workplace Mitigation in Restaurant Oven WorkersCompleted2026-01-01
Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver DiseaseThe Cleveland ClinicRecruiting2025-12-17
Dynamic Q Angle and Core Endurance in Adolescent Athletes With Patellofemoral Pain SyndromeEastern Mediterranean UniversityCompleted2025-12-01
Implementation of a Pain Management Plan in Major Open Abdominal Surgeries.National and Kapodistrian University of AthensRecruiting2025-11-22
Risk Assessment of Mild Traumatic Brain Injury in Military TrainingCharles University, Czech RepublicEnrolling By Invitation2025-11-04
Preoperative Anxiety and One-year Patient-reported Outcomes in Orthopedic Surgery Patients Receiving Enhanced Recovery After Surgery or Conventional CareBuddhist Tzu Chi General HospitalRecruiting2025-11-01
Clinical Utility of the Numerical Verbal Scale (NVS) and the Pain and Functional Activity Scale (PFAS) in the Management of Rescue Analgesia in Acute Postoperative Pain. Randomized Study.Fundacin Biomedica Galicia SurRecruiting2025-10-30
Ambient Air and Noise Effect on Cardiovascular Health Risk and Lifestyle Intervention to Attenuate It (METSGREEN)Recruiting2025-10-24
Climate Change Education Based on the IMB Model for Pregnant WomenCukurova UniversityCompleted2025-10-20
Trial of Social Work Services in Fracture Clinic SettingRecruiting2025-10-06
Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)Rezera (formerly NodThera Limited)Completed2025-10-02
Transplacental Neonatal Transfer of Lidocaine During Urgent Caesarean DeliveryHôpital de la Croix-RousseCompleted2025-10-01
Effects of Climate Change Education on Pregnant WomenDicle UniversityCompleted2025-09-24
Assessing PFAS Exposure for Better HealthMillion Marker Wellness, IncCompleted2025-09-01
Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant MesotheliomaNational Cancer Center, ChinaNot Yet Recruiting2025-09-01
Changes in Body Composition Following Pharmacological Treatment for Obesity.Hospital San Carlos, MadridEnrolling By Invitation2025-09-01
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide TreatmentUniversity Hospital, Gentofte, CopenhagenCompleted2025-09-01
Environmental Pollutants and Neurological DisordersBeijing Tiantan HospitalRecruiting2025-08-01
Housing, Environment, And Living Conditions for Transformed HealthUniversity of Alabama at BirminghamActive Not Recruiting2025-06-18
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaNational Cancer Institute (NCI)Recruiting2025-06-05
Combined Effects of Statins and Exercise on Training Sensitive Health MarkersUniversity of the Faroe IslandsCompleted2025-05-01
Effect of Haptonomy on Prenatal Attachment and Fear of Childbirth in Primiparous CouplesNigde Omer Halisdemir UniversityRecruiting2025-03-26
Hydrodissection Tunneling Technique on Recurrent Laryngeal Nerve Protection During ThyroidectomyWest China HospitalCompleted2025-03-01
Modafinil to Optimize the Performance of Cold-Stressed Sleep-Deprived PersonnelUnited States Army Research Institute of Environmental MedicineRecruiting2025-02-18
Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse EventsAriel UniversityCompleted2025-01-30
The Sleep2BWell TrialColumbia UniversityRecruiting2025-01-25
Patient Centered Post-Op Pain Management Software Tool Interventional Study Verses Standard of CareNova Scotia Health AuthorityCompleted2025-01-07
A Study of a Weight Loss Intervention in People With Endometrial CancerMemorial Sloan Kettering Cancer CenterActive Not Recruiting2024-12-19
Urban Exposome and Biological AgeUniversity of PaviaCompleted2024-11-21
PFAS Exposure and Immune Response to Vaccination in AdultsRutgers, The State University of New JerseyCompleted2024-11-04
Air Pollution and Cardiovascular Disease in Qatar: an Interventional Study to Reduce Blood PressureWeill Cornell Medical College in QatarRecruiting2024-11-03
COPD Prevalence and Risk Factors Among Saudi Adults Over 18 in TaifTaif UniversityCompleted2024-10-24
Virtual Reality to Reduce Pain and Anxiety During Extracorporeal Shock Wave LithotripsyZealand University HospitalCompleted2024-10-24
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.Recruiting2024-10-22
Improving In-hospital and Post-discharge Patient Education for Mild Traumatic Brain InjuryMedical College of WisconsinEnrolling By Invitation2024-09-11
Multidimensional Omics Analysis in Malignant Pleural MesotheliomaAzienda USL Reggio Emilia - IRCCSRecruiting2024-08-30
Exercise Reset for Concussion in a Military EnvironmentState University of New York at BuffaloCompleted2024-08-07
Observation of Environment and Reproductive-Endocrine EffectsNational Institute of Environmental Health Sciences (NIEHS)Recruiting2024-07-01
Feasibility of Aerobic Exercise for Recovery From Work-related ConcussionState University of New York at BuffaloCompleted2024-07-01
Adapting a Mammography Decision Aid to Support Women Living in a Community Contaminated by PFASTrustees of Dartmouth CollegeCompleted2024-05-06
Cohort Study on Plant-based Diets (COPLANT Study)German Federal Institute for Risk AssessmentRecruiting2024-04-09
Personalizing Veterans' Lung Cancer Screening and DiagnosisVA Office of Research and DevelopmentEnrolling By Invitation2024-04-03
Evaluation of Response by FLT PET in MesotheliomaAnkara UniversityUnknown2024-04-01
Cancer Pain Management Using a Web-based InterventionVanderbilt UniversityRecruiting2024-02-20
Impact GLP-1 Agonists Following BariatricUniversity of Missouri-ColumbiaRecruiting2024-02-01
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing MesothelinNational Cancer Institute (NCI)Withdrawn2024-01-31
Pharmacodynamic and Short-term Effects of Half-dose Ticagrelor With or Without Aspirin vs DAPT From Day of PCI in CCSKaohsiung Veterans General HospitalCompleted2024-01-03
Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in FirefightersNational Cancer Institute (NCI)Active Not Recruiting2023-12-04
Antibiotics and Vaccine Immune Responses StudySouth Australian Health and Medical Research InstituteRecruiting2023-11-23
Immune Microenvironment and Gene Expression Profiling in MesotheliomaIstituto Oncologico Veneto IRCCSCompleted2023-11-02
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple MyelomaRegeneron PharmaceuticalsRecruiting2023-09-18
Rural Expanded Access to OUD Care & Linkage Using Toxicologists for Telehealth Initiated TreatmentEmory UniversityCompleted2023-08-30
Firefighter Collaborative Research ProjectUniversity of ArizonaActive Not Recruiting2023-06-22
Speckle Tracking Echocardiography as a Tool for Early Diagnosis of Impaired Fetal Growth Twin PregnanciesUniversity Hospital, GhentRecruiting2023-06-22
Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE variaTionSFondazione IRCCS Policlinico San Matteo di PaviaRecruiting2023-06-15
Healing Opioid Misuse and Pain Through Engagement (HOPE) TrialUniversity of New MexicoActive Not Recruiting2023-05-05
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETAUniversity of Alabama at BirminghamCompleted2023-05-04
Comparing Concussion Education TypesWithdrawn2023-04-19
Sex Disparities in Hypoxic Vasodilation and Impact of ObesityUniversity of Missouri-ColumbiaRecruiting2023-03-14
Predict Severe Traumatic Brain InjuryUniversity of ChicagoRecruiting2023-02-20
Artificial Intelligence in Lung Cancer ScreeningScientific Institute San RaffaeleCompleted2022-12-02
Semaglutide 2.4 mg in Patients With Poor Weight-lossUniversity College, LondonCompleted2022-11-01
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy SmokersNational Cancer Institute (NCI)Recruiting2022-09-21
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Recruiting2022-09-20
Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCCZhejiang Provincial People's HospitalRecruiting2022-09-01
TNF-α Treatment of Blast-Induced TinnitusWayne State UniversityActive Not Recruiting2022-07-01
Hyperbaric Oxygen Effects on Persistent Post-concussive SymptomsEssentia HealthCompleted2022-06-28
Young Adults With Early-onset Obesity Treated With SemaglutideCompleted2022-05-30
Dexamethasone to Target Stress and Immune System Mechanisms Underlying Alcohol CravingStony Brook UniversityCompleted2022-03-11
Effect of HITHOC After Pleurectomy Decortication for Treatment of Malignant Pleural MesotheliomaAin Shams UniversityUnknown2022-03-01
Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural MesotheliomaHospices Civils de LyonUnknown2022-02-11
Environmental Factors and Thyroid CancerIcahn School of Medicine at Mount SinaiRecruiting2022-02-03
Plastic Waste and Human Health Effects in GuatemalaEmory UniversityCompleted2022-01-31
Control Network Neuromodulation to Enhance Cognitive Training in Complex Traumatic Brain InjuryUniversity of New MexicoRecruiting2022-01-21
Positive Assurance and mTBIInova Health Care ServicesActive Not Recruiting2021-10-15
Sub-symptom Threshold Aerobic Exercise After Mild Traumatic Brain InjuryOslo University HospitalCompleted2021-10-01
Discovering Cancer Risks From Environmental Contaminants and Maternal/Child HealthUniversity of California, San FranciscoTerminated2021-09-01
Lung Cancer Screening in a Population Exposed to Occupational Lung CarcinogensCentre Hospitalier Intercommunal CreteilRecruiting2021-07-22
Pain and Opioids: Integrated Treatment In VeteransUniversity of New MexicoActive Not Recruiting2021-07-01
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 DiabetesNovo Nordisk A/SCompleted2021-06-15
SmART-TBI: Supplementation With Amino Acid Rehabilitative Therapy in TBIVA Office of Research and DevelopmentCompleted2021-06-01
Auriculotherapy in the Treatment of Pre-Operative AnxietyCompleted2021-04-13
Neuromodulation and Neurorehabilitation for mTBINorthwestern UniversityRecruiting2021-04-01
Effects of Silica and Asbestos Fibres on the Efferocytosis Capacities of MacrophagesRennes University HospitalCompleted2021-03-31
Secondhand Tobacco Smoke and Cardiovascular DiseaseUniversity of California, San FranciscoRecruiting2021-03-30
Vagal Nerve Stimulation in mTBIVA Office of Research and DevelopmentCompleted2021-02-25
NIH-AARP Diet and Health Secondary Research Study Based on OH95CN025 DataNational Cancer Institute (NCI)Active Not Recruiting2021-02-09
Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)Children's Hospital of Orange CountyRecruiting2021-02-01
Factors Influencing Fertility or Pregnancy HealthNational Institute of Environmental Health Sciences (NIEHS)Active Not Recruiting2020-10-19
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus NephritisActive Not Recruiting2020-08-10
Clinical Evaluation of the i-STAT TBI TestAbbott Point of CareCompleted2020-07-31
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic LeukaemiaRecruiting2020-07-13
PARA (Pancreatic Adenocarcinoma Etiology: Role of Asbestos) Study of Risk Factors for Exocrine Pancreatic Neoplasms.IRCCS Azienda Ospedaliero-Universitaria di BolognaActive Not Recruiting2020-05-28
Transcranial Ultrasonography for the Management of Patients With Mild TBIUniversity Hospital, GrenobleCompleted2020-02-01
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent IohexolNRG OncologyActive Not Recruiting2020-01-15
Investigation of the Anti-Cancer Activity of Artichoke Extract in an Asbestos-Exposed PopulationOntario Clinical Oncology Group (OCOG)Completed2019-11-05
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting2019-07-24
Mesothelioma Early Detection by VOCsHenry Ford Health SystemTerminated2019-06-05
Effects of Semaglutide in HIV-Associated LipohypertrophyCase Western Reserve UniversityCompleted2019-05-16
Pilot rTMS for AUD+mTBIVA Office of Research and DevelopmentTerminated2019-03-21
Occupational Exposure to Dust and the Relationship With the Respiratory Symptoms, Lung Function Among Construction Workers of the University of Malaysia Sabah (UMS)Universiti Malaysia SabahCompleted2019-01-01
A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy SubjectsNovartis PharmaceuticalsCompleted2018-12-21
Study of Exposure to Chemicals in Consumer ProductsNational Institute of Environmental Health Sciences (NIEHS)Completed2018-08-07
Household Air Pollution and Health: A Multi-country LPG Intervention TrialEmory UniversityCompleted2018-05-07
MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma.Papworth Hospital NHS Foundation TrustCompleted2017-08-10
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive DisorderNational Institute of Mental Health (NIMH)Recruiting2017-05-25
Idiopathic Pulmonary Fibrosis Job Exposures StudyImperial College LondonCompleted2017-05-01
CheckpOiNt Blockade For Inhibition of Relapsed MesotheliomaUniversity of SouthamptonCompleted2017-03-28
AIRWEIGHS: Investigating Obesity as a Susceptibility Factor for Air Pollution in Childhood AsthmaJohns Hopkins UniversityActive Not Recruiting2016-08
Selinexor and Backbone Treatments of Multiple Myeloma PatientsKaryopharm Therapeutics IncRecruiting2015-10
Concussion Goody Bag StudyAnn & Robert H Lurie Children's Hospital of ChicagoWithdrawn2015-10
Prevention Program to Reduce Injury Disparities Among Latino Day LaborersThe University of Texas Health Science Center, HoustonCompleted2015-10-26
Mesothelioma and Radical Surgery 2Royal Brompton & Harefield NHS Foundation TrustUnknown2015-05
Screening of Alberta Asbestos Exposed Workers for Lung Cancer and MesotheliomaUniversity of CalgaryTerminated2015-01-01
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)Active Not Recruiting2014-12-17
A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease PatientsNeuroDerm LtdCompleted2014-01-06
Ganetespib With Platinum, in Patients With Malignant Pleural MesotheliomaUniversity College, LondonCompleted2013-08
Clinical and Histopathologic Characteristics of BAP1 MutationsMemorial Sloan Kettering Cancer CenterCompleted2013-01
Comparison of the Ultra-low-dose Veo Algorithm With the Gold Standard Filtered Back Projection for Detecting Pulmonary Asbestos-related ConditionsUniversity Hospital, Clermont-FerrandCompleted2012-09
Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos ExposureUniversity Hospital, CaenTerminated2012-09
Observational Prospective Analysis of Biological Characteristics of Mesothelioma PatientsCompleted2011-04
Developing Field Tools for Real-Time Assessment of Exposure to Psychosocial Stress and Drug Use in an Outpatient Treatment PopulationNational Institute on Drug Abuse (NIDA)Completed2009-07-14
Short Neoadjuvant Hemithoracic IMRT for MPMUniversity Health Network, TorontoCompleted2008-10
Tamsulosin and the Risk of Serious Adverse EventsLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sActive Not Recruiting2008-01-01
Project Viva: a Longitudinal Study of Health for the Next GenerationHarvard Pilgrim Health CareActive Not Recruiting1999-01

Recalls

Products recalled for the same contaminants.

Recalls whose stated reason names benzene, NDMA, ethylene oxide or PFAS, with the firm that recalled each product.

302 recalls · updated November 2, 2026 · newest first

Recalling firmRecallReasonClassStarted
Owen Biosciences Inc.D-0452-2026Chemical contamination: Presence of benzeneClass II2026-03-03
Owen Biosciences Inc.D-0454-2026Chemical contamination: Presence of benzeneClass II2026-03-03
Owen Biosciences Inc.D-0455-2026Chemical contamination: Presence of benzeneClass II2026-03-03
Owen Biosciences Inc.D-0453-2026Chemical contamination: Presence of benzeneClass II2026-03-03
Private Label Skin Care Inc.D-0668-2025Chemical Contamination: This recall has been initiated due to elevated levels of benzene that was discovered during post consume awareness with benzoyl peroxide products.Class II2025-09-12
Private Label Skin Care Inc.D-0663-2025Chemical Contamination: This recall has been initiated due to elevated levels of benzene that was discovered during post consume awareness with benzoyl peroxide products.Class II2025-09-12
Private Label Skin Care Inc.D-0666-2025Chemical Contamination: This recall has been initiated due to elevated levels of benzene that was discovered during post consume awareness with benzoyl peroxide products.Class II2025-09-12
Private Label Skin Care Inc.D-0667-2025Chemical Contamination: This recall has been initiated due to elevated levels of benzene that was discovered during post consume awareness with benzoyl peroxide products.Class II2025-09-12
Private Label Skin Care Inc.D-0664-2025Chemical Contamination: This recall has been initiated due to elevated levels of benzene that was discovered during post consume awareness with benzoyl peroxide products.Class II2025-09-12
Private Label Skin Care Inc.D-0665-2025Chemical Contamination: This recall has been initiated due to elevated levels of benzene that was discovered during post consume awareness with benzoyl peroxide products.Class II2025-09-12
American Contract Systems Inc.Z-0180-2026Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed.Class II2025-09-04
American Contract Systems Inc.Z-0185-2026Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed.Class II2025-09-04
American Contract Systems Inc.Z-0174-2026Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed.Class II2025-09-04
American Contract Systems Inc.Z-0173-2026Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed.Class II2025-09-04
American Contract Systems Inc.Z-0187-2026Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed.Class II2025-09-04
American Contract Systems Inc.Z-0170-2026Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed.Class II2025-09-04
American Contract Systems Inc.Z-0184-2026Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed.Class II2025-09-04
American Contract Systems Inc.Z-0171-2026Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed.Class II2025-09-04
American Contract Systems Inc.Z-0186-2026Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed.Class II2025-09-04
American Contract Systems Inc.Z-0182-2026Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed.Class II2025-09-04
American Contract Systems Inc.Z-0175-2026Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed.Class II2025-09-04
American Contract Systems Inc.Z-0181-2026Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed.Class II2025-09-04
American Contract Systems Inc.Z-0172-2026Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed.Class II2025-09-04
American Contract Systems Inc.Z-0176-2026Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed.Class II2025-09-04
American Contract Systems Inc.Z-0183-2026Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed.Class II2025-09-04
American Contract Systems Inc.Z-0178-2026Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed.Class II2025-09-04
American Contract Systems Inc.Z-0177-2026Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed.Class II2025-09-04
American Contract Systems Inc.Z-0179-2026Identified products were re-gassed (sterilized more than once) after a nonconformance occurred during the initial Ethylene Oxide (EO) gas injection process. These products have not been validated for exposure to multiple sterilization cycles. Therefore, product quality, safety, and effectiveness cannot be confirmed for product that was re-gassed.Class II2025-09-04
American Contract Systems, Inc.Z-1916-2025Test results for cast padding component included in procedure trays shows Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals exceeded residual limits, which may lead to a possible loss or lack of functionality that may lead to a delay or prolonged treatment/procedure/therapy.Class II2025-04-21
Alchemee, LLCD-0360-2025Chemical contamination: Presence of benzeneClass II2025-03-12
Alchemee, LLCD-0359-2025Chemical contamination: Presence of benzeneClass II2025-03-12
Fruit Of The Earth, Inc.D-0284-2025Chemical contamination: presence of benzeneClass II2025-03-11
Fruit Of The Earth, Inc.D-0283-2025Chemical contamination: presence of benzeneClass II2025-03-11
L'Oreal USAD-0419-2025cGMP Deviations: The recall was initiated due to detected trace levels of benzene in a specific lot of this product lot (MYX46W), however out of an abundance of caution, the firm voluntarily recalled all La Roche-Posay Effaclar Duo Dual Action Acne Treatment lots.Class II2025-03-05
L'Oreal USAD-0418-2025cGMP Deviations: The recall was initiated due to detected trace levels of benzene in a specific lot of this product lot (MYX46W), however out of an abundance of caution, the firm voluntarily recalled all La Roche-Posay Effaclar Duo Dual Action Acne Treatment lots.Class II2025-03-05
L'Oreal USAD-0417-2025Chemical Contamination: This recall has been initiated due to detected trace levels of benzene.Class II2025-03-05
Strides Pharma, Inc.D-0294-2025Presence of foreign substance: Presence of Benzene.Class II2025-03-05
Strides Pharma, Inc.D-0293-2025Presence of foreign substance: Presence of Benzene.Class II2025-03-05
Sigan Industries Group Inc.D-0274-2025Chemical Contamination: Presence of benzeneClass II2025-02-28
Denison Pharmaceuticals, LLCD-0273-2025Chemical Contamination: Presence of benzene.Class II2025-02-24
American Contract Systems IncZ-2275-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2288-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2310-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2280-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2281-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2305-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2311-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2301-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2292-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2279-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2300-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2287-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2293-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2290-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2283-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2286-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2274-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2278-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2308-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2294-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2297-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2284-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2303-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2282-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2306-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2302-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2291-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2276-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2309-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2307-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2296-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2285-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2299-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2277-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2304-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2312-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2289-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2295-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
American Contract Systems IncZ-2298-2024Ethylene Oxide/Ethylene Chlorohydrin (EO/ECH) residuals for the cast padding component exceeded the residual limits for permanent exposure devices as indicated by ANSI/AAMI/ISO 10993-7/(R)2012.Class II2024-05-15
CovidienZ-1330-2024Packs including 5 laparotomy sponges may contain incorrect product with a blue loop, X-ray detectable feature, and ethylene oxide treatment; however, this incorrect product wasn't steam pre-treated prior to sterilization, and has no RF tag, which if non-sterile, may lead to infection, tissue trauma, and sepsis, and if in the scannable area, would lead a "CLEAR" display.Class II2024-02-21
Insight Pharmaceuticals LLC, a Prestige Consumer Healthcare companyD-0346-2024Chemical Contamination; presence of benzene.Class I2024-02-01
Covidien, LPZ-1697-2024One lot of product was exposed to more than the approved number of Ethylene Oxide (EO) sterilization cycles. This may decrease the tensile strength of the sutures over time, which could result in harms such as wound dehiscence, hemorrhage, blood loss, bleeding, tissue breakdown, peritonitis, unspecified infection, vision loss (when used in ophthalmic application), and/or prolonged surgery.Class II2024-01-25
Insight Pharmaceuticals LLC, a Prestige Consumer Healthcare companyD-0236-2024Chemical Contamination: presence of benzeneClass I2023-12-21
Insight Pharmaceuticals CorporationD-0151-2024Chemical Contamination; presence of benzene.Class I2023-11-22
Teva Pharmaceuticals USA IncD-0441-2023CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.Class II2023-02-22
Steris CorporationZ-0781-2023Biological indicator (BI) used to promote growth of the G. stearothermophilus and B. atrophaeus spores was inconsistent in promoting growth throughout lot , some BIs within the lot performed as intended while others did not. When used to monitor steam and ethylene oxide sterilization cycles, the potential hazard is that the BI will show no growth indicating that the cycle was effective, even if itClass II2022-12-12
Steris CorporationZ-0779-2023Biological indicator (BI) used to promote growth of the G. stearothermophilus and B. atrophaeus spores was inconsistent in promoting growth throughout lot , some BIs within the lot performed as intended while others did not. When used to monitor steam and ethylene oxide sterilization cycles, the potential hazard is that the BI will show no growth indicating that the cycle was effective, even if itClass II2022-12-12
Steris CorporationZ-0780-2023Biological indicator (BI) used to promote growth of the G. stearothermophilus and B. atrophaeus spores was inconsistent in promoting growth throughout lot , some BIs within the lot performed as intended while others did not. When used to monitor steam and ethylene oxide sterilization cycles, the potential hazard is that the BI will show no growth indicating that the cycle was effective, even if itClass II2022-12-12
Steris CorporationZ-0778-2023Biological indicator (BI) used to promote growth of the G. stearothermophilus and B. atrophaeus spores was inconsistent in promoting growth throughout lot , some BIs within the lot performed as intended while others did not. When used to monitor steam and ethylene oxide sterilization cycles, the potential hazard is that the BI will show no growth indicating that the cycle was effective, even if itClass II2022-12-12
Salon Technologies International IncD-0002-2023Chemical Contamination: product found to contain benzeneClass I2022-09-14
Edgewell Personal Care Brands, LLCD-0212-2024Chemical contamination: presence of benzeneClass I2022-07-29
Crown Prince, IncF-1551-2022Detectable levels of Per- and polyfluoroalkyl substances (PFAS).Class II2022-07-15
Bumble Bee Foods, LLCF-1508-2022Detectable levels of Per- and polyfluoroalkyl substances (PFAS).Class II2022-07-06
Unilever United States Inc.D-0210-2024Chemical contamination: presence of benzeneClass I2022-03-30
Unilever United States Inc.D-0211-2024CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzeneClass II2022-03-30
Best Brands Consumer Products, Inc.D-0877-2022Chemical Contamination; FDA analysis found product to contain benzeneClass I2022-03-29
TCP HRB ACQUISITON LLCD-0208-2024Chemical contamination: Presence of benzeneClass I2022-02-16
TCP HRB ACQUISITON LLCD-0207-2024Chemical contamination: Presence of benzeneClass I2022-02-16
TCP HRB ACQUISITON LLCD-0209-2024Chemical contamination: Presence of benzeneClass I2022-02-16
RemedyRepack Inc.D-0366-2022CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.Class II2021-12-30
VIONA PHARMACEUTICALS INCD-0392-2022CGMP Deviations- Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.Class II2021-12-27
The Procter & Gamble CompanyD-0248-2024CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzeneClass II2021-11-23
The Procter & Gamble CompanyD-0249-2024CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzeneClass II2021-11-23
The Procter & Gamble CompanyD-0242-2024Chemical contamination: presence of benzeneClass I2021-11-23
The Procter & Gamble CompanyD-0247-2024CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzeneClass II2021-11-23
The Procter & Gamble CompanyD-0252-2024CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzeneClass II2021-11-23
The Procter & Gamble CompanyD-0251-2024CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzeneClass II2021-11-23
The Procter & Gamble CompanyD-0253-2024CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzeneClass II2021-11-23
The Procter & Gamble CompanyD-0244-2024Chemical contamination: presence of benzeneClass I2021-11-23
The Procter & Gamble CompanyD-0238-2024Chemical contamination: presence of benzeneClass I2021-11-23
The Procter & Gamble CompanyD-0239-2024CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzeneClass II2021-11-23
The Procter & Gamble CompanyD-0246-2024Chemical contamination: presence of benzeneClass I2021-11-23
The Procter & Gamble CompanyD-0256-2024CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzeneClass II2021-11-23
The Procter & Gamble CompanyD-0254-2024CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzeneClass II2021-11-23
The Procter & Gamble CompanyD-0250-2024CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzeneClass II2021-11-23
The Procter & Gamble CompanyD-0241-2024Chemical contamination: presence of benzeneClass I2021-11-23
The Procter & Gamble CompanyD-0240-2024Chemical contamination: presence of benzeneClass I2021-11-23
The Procter & Gamble CompanyD-0243-2024Chemical contamination: presence of benzeneClass I2021-11-23
The Procter & Gamble CompanyD-0255-2024CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzeneClass II2021-11-23
The Procter & Gamble CompanyD-0245-2024CGMP Deviation; manufactured at the same facility where other lots were found to be contaminated with benzeneClass II2021-11-23
Blistex IncD-0159-2024Chemical contamination: Presence of benzeneClass I2021-11-17
VIRGIN SCENT INCD-0782-2022Chemical Contamination: presence of benzene, acetaldehyde, and acetal.Class I2021-10-26
Karl Storz EndoscopyZ-0442-2022To ensure sterilization effectiveness, sterilization tray instructions for use were updated and now state 1) udel trays may be used with flexible endoscopes with lumen diameters greater-than-or-equal to 1.2mm and maximum length of 845mm and 2) ethylene oxide is excluded as a sterilization modality.Class II2021-10-15
Bayer Healthcare Pharmaceuticals Inc.D-0253-2022Chemical Contamination: presence of benzeneClass I2021-10-01
Bayer Healthcare Pharmaceuticals Inc.D-0251-2022Chemical Contamination: presence of benzeneClass I2021-10-01
Bayer Healthcare Pharmaceuticals Inc.D-0242-2022cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene.Class II2021-10-01
Bayer Healthcare Pharmaceuticals Inc.D-0247-2022Chemical Contamination: presence of benzeneClass I2021-10-01
Bayer Healthcare Pharmaceuticals Inc.D-0236-2022cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene.Class II2021-10-01
Bayer Healthcare Pharmaceuticals Inc.D-0249-2022Chemical Contamination: presence of benzeneClass I2021-10-01
Bayer Healthcare Pharmaceuticals Inc.D-0239-2022cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene.Class II2021-10-01
Bayer Healthcare Pharmaceuticals Inc.D-0246-2022Chemical Contamination: presence of benzeneClass I2021-10-01
Bayer Healthcare Pharmaceuticals Inc.D-0240-2022cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene.Class II2021-10-01
Bayer Healthcare Pharmaceuticals Inc.D-0250-2022Chemical Contamination: presence of benzeneClass I2021-10-01
Bayer Healthcare Pharmaceuticals Inc.D-0237-2022cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene.Class II2021-10-01
Bayer Healthcare Pharmaceuticals Inc.D-0254-2022cGMP Deviations: LOTRIMIN AF (Tolnaftate 1%) manufactured at the same facility where other lots were found to be contaminated with benzene.Class II2021-10-01
Bayer Healthcare Pharmaceuticals Inc.D-0243-2022cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene.Class II2021-10-01
Bayer Healthcare Pharmaceuticals Inc.D-0252-2022Chemical Contamination: presence of benzeneClass I2021-10-01
Bayer Healthcare Pharmaceuticals Inc.D-0238-2022cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene.Class II2021-10-01
Bayer Healthcare Pharmaceuticals Inc.D-0241-2022cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene.Class II2021-10-01
Bayer Healthcare Pharmaceuticals Inc.D-0245-2022cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene.Class II2021-10-01
Bayer Healthcare Pharmaceuticals Inc.D-0244-2022cGMP Deviations: manufactured at the same facility where other lots were found to be contaminated with benzene.Class II2021-10-01
Bayer Healthcare Pharmaceuticals Inc.D-0248-2022Chemical Contamination: presence of benzeneClass I2021-10-01
Beiersdorf IncD-0013-2022Chemical contamination; presence of benzeneClass I2021-09-30
Beiersdorf IncD-0011-2022Chemical contamination; presence of benzeneClass I2021-09-30
Beiersdorf IncD-0014-2022Chemical contamination; presence of benzeneClass I2021-09-30
Beiersdorf IncD-0012-2022Chemical contamination; presence of benzeneClass I2021-09-30
Beiersdorf IncD-0010-2022Chemical contamination; presence of benzeneClass I2021-09-30
Johnson & Johnson Consumer, Inc.D-0844-2021Chemical Contamination: presence of benzeneClass I2021-07-14
Johnson & Johnson Consumer, Inc.D-0845-2021Chemical Contamination: presence of benzeneClass I2021-07-14
VIONA PHARMACEUTICALS INCD-0640-2021CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.Class II2021-06-01
Covidien, LPZ-1868-2021The company was notified by their supplier of sterilization services for airway products in Italy of potential deviations from validated parameters for ethylene oxide sterilization.Class II2021-04-29
Covidien, LPZ-1867-2021The company was notified by their supplier of sterilization services for airway products in Italy of potential deviations from validated parameters for ethylene oxide sterilization.Class II2021-04-29
Covidien, LPZ-1866-2021The company was notified by their supplier of sterilization services for airway products in Italy of potential deviations from validated parameters for ethylene oxide sterilization.Class II2021-04-29
Covidien, LPZ-1869-2021The company was notified by their supplier of sterilization services for airway products in Italy of potential deviations from validated parameters for ethylene oxide sterilization.Class II2021-04-29
Preferred Pharmaceuticals, Inc.D-0385-2021CMGP Deviations: Presence of NDMA impurity detected in product and exceed the Acceptable Daily Intake Limit (ADI) of 96ng/day.Class II2021-04-28
Scentsational Soaps & Candles IncD-0682-2021Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde.Class I2021-04-27
Scentsational Soaps & Candles IncD-0677-2021Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde.Class I2021-04-27
Scentsational Soaps & Candles IncD-0673-2021Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde.Class I2021-04-27
Scentsational Soaps & Candles IncD-0668-2021Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde.Class I2021-04-27
Scentsational Soaps & Candles IncD-0678-2021Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde.Class I2021-04-27
Scentsational Soaps & Candles IncD-0666-2021Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde.Class I2021-04-27
Scentsational Soaps & Candles IncD-0671-2021Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde.Class I2021-04-27
Scentsational Soaps & Candles IncD-0672-2021Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde.Class I2021-04-27
Scentsational Soaps & Candles IncD-0681-2021Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde.Class I2021-04-27
Scentsational Soaps & Candles IncD-0670-2021Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde.Class I2021-04-27
Scentsational Soaps & Candles IncD-0679-2021Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde.Class I2021-04-27
Scentsational Soaps & Candles IncD-0676-2021Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde.Class I2021-04-27
Scentsational Soaps & Candles IncD-0674-2021Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde.Class I2021-04-27
Scentsational Soaps & Candles IncD-0675-2021Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde.Class I2021-04-27
Scentsational Soaps & Candles IncD-0680-2021Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde.Class I2021-04-27
Scentsational Soaps & Candles IncD-0684-2021Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde.Class I2021-04-27
Scentsational Soaps & Candles IncD-0683-2021Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde.Class I2021-04-27
Scentsational Soaps & Candles IncD-0669-2021Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde.Class I2021-04-27
Scentsational Soaps & Candles IncD-0667-2021Chemical contamination: product found to be contaminated with methanol (wood alcohol), benzene and acetaldehyde.Class I2021-04-27
Spes MedicaZ-1968-2021The supplier informed them of possible deviations of the parameters/processes defined for ethylene oxide sterilization.Class II2021-04-08
Spes MedicaZ-1967-2021The supplier informed them of possible deviations of the parameters/processes defined for ethylene oxide sterilization.Class II2021-04-08
Spes MedicaZ-1971-2021The supplier informed them of possible deviations of the parameters/processes defined for ethylene oxide sterilization.Class II2021-04-08
Spes MedicaZ-1970-2021The supplier informed them of possible deviations of the parameters/processes defined for ethylene oxide sterilization.Class II2021-04-08
Spes MedicaZ-1969-2021The supplier informed them of possible deviations of the parameters/processes defined for ethylene oxide sterilization.Class II2021-04-08
Covidien LlcZ-1419-2021Potential for the pouch to contain an extra laminate layer, creating the potential for the device sterility to be compromised. The inclusion of an additional laminate layer in the package may also impact complete de-gassing of the sterilization gas, Ethylene Oxide and may result in a potentially increased risk for patient infection and/or potential exposure to Ethylene Oxide retained in the pouchClass II2021-03-23
Nostrum Laboratories IncD-0249-2021CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level.Class II2021-01-25
Nostrum Laboratories IncD-0227-2021CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2021-01-04
Preferred Pharmaceuticals, Inc.D-0077-2021CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.Class II2020-11-01
Nostrum Laboratories IncD-0068-2021CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-10-23
Nostrum Laboratories IncD-0067-2021CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-10-23
Direct RxD-0058-2021CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level (per manufacturer)Class II2020-10-12
RemedyRepack Inc.D-0050-2021CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level (per manufacturer)Class II2020-10-11
Denton Pharma, Inc.D-0057-2021CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level (per manufacturer)Class II2020-10-08
Denton Pharma, Inc.D-0056-2021CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level (per manufacturer)Class II2020-10-08
PD-Rx Pharmaceuticals, Inc.D-0060-2021CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level (per manufacturer)Class II2020-10-06
PD-Rx Pharmaceuticals, Inc.D-0059-2021CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level (per manufacturer)Class II2020-10-06
Marksans Pharma LimitedD-0061-2021CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-10-02
Marksans Pharma LimitedD-0062-2021CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-10-02
SUN PHARMACEUTICAL INDUSTRIES INCD-0002-2021CGMP Deviations: Detection of N-nitrosodimethylamine (NDMA) impurity in finished drug product.Class II2020-09-23
Karl Storz EndoscopyZ-2892-2020Updated sterilization instructions are being provided to ensure 1) a specific sterilization tray is not used, and 2) ethylene oxide sterilization is never used on certain reusable flexible intubation endoscopes with total lumen lengths greater than 850mm. Incompletely sterilized endoscopes might introduce infectious agents into patient airways, resulting in infection.Class II2020-07-27
Karl Storz EndoscopyZ-2895-2020Updated sterilization instructions are being provided to ensure 1) a specific sterilization tray is not used, and 2) ethylene oxide sterilization is never used on certain reusable flexible intubation endoscopes with total lumen lengths greater than 850mm. Incompletely sterilized endoscopes might introduce infectious agents into patient airways, resulting in infection.Class II2020-07-27
Karl Storz EndoscopyZ-2890-2020Updated sterilization instructions are being provided to ensure 1) a specific sterilization tray is not used, and 2) ethylene oxide sterilization is never used on certain reusable flexible intubation endoscopes with total lumen lengths greater than 850mm. Incompletely sterilized endoscopes might introduce infectious agents into patient airways, resulting in infection.Class II2020-07-27
Karl Storz EndoscopyZ-2893-2020Updated sterilization instructions are being provided to ensure 1) a specific sterilization tray is not used, and 2) ethylene oxide sterilization is never used on certain reusable flexible intubation endoscopes with total lumen lengths greater than 850mm. Incompletely sterilized endoscopes might introduce infectious agents into patient airways, resulting in infection.Class II2020-07-27
Karl Storz EndoscopyZ-2897-2020Updated sterilization instructions are being provided to ensure 1) a specific sterilization tray is not used, and 2) ethylene oxide sterilization is never used on certain reusable flexible intubation endoscopes with total lumen lengths greater than 850mm. Incompletely sterilized endoscopes might introduce infectious agents into patient airways, resulting in infection.Class II2020-07-27
Karl Storz EndoscopyZ-2896-2020Updated sterilization instructions are being provided to ensure 1) a specific sterilization tray is not used, and 2) ethylene oxide sterilization is never used on certain reusable flexible intubation endoscopes with total lumen lengths greater than 850mm. Incompletely sterilized endoscopes might introduce infectious agents into patient airways, resulting in infection.Class II2020-07-27
Karl Storz EndoscopyZ-2894-2020Updated sterilization instructions are being provided to ensure 1) a specific sterilization tray is not used, and 2) ethylene oxide sterilization is never used on certain reusable flexible intubation endoscopes with total lumen lengths greater than 850mm. Incompletely sterilized endoscopes might introduce infectious agents into patient airways, resulting in infection.Class II2020-07-27
Karl Storz EndoscopyZ-2891-2020Updated sterilization instructions are being provided to ensure 1) a specific sterilization tray is not used, and 2) ethylene oxide sterilization is never used on certain reusable flexible intubation endoscopes with total lumen lengths greater than 850mm. Incompletely sterilized endoscopes might introduce infectious agents into patient airways, resulting in infection.Class II2020-07-27
Lupin Pharmaceuticals Inc.D-1382-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-07-07
Lupin Pharmaceuticals Inc.D-1385-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-07-07
Lupin Pharmaceuticals Inc.D-1384-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-07-07
Lupin Pharmaceuticals Inc.D-1383-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-07-07
Granules Pharmaceuticals IncD-1386-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-07-03
Sutter Medizintechnik GmbHZ-2744-2020The label on the cardbox and the blister show the correct symbols for sterilization using irradiation and storage at 5 C to 40 C, the package insert (IFU) is labelled incorrectly. It shows the symbol for sterilization using Ethylene Oxide with the description for sterilization using irradiation.Class II2020-06-23
Preferred Pharmaceuticals, Inc.D-1364-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.Class II2020-06-17
The Harvard Drug GroupD-1360-2020CGMP Deviation: Potential presence of Nitrosodimethylamine (NDMA) Impurity above the established levels.Class II2020-06-12
Lupin Pharmaceuticals Inc.D-1334-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-06-11
Marksans Pharma LimitedD-1356-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-06-05
PD-Rx Pharmaceuticals, Inc.D-1333-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-06-05
PD-Rx Pharmaceuticals, Inc.D-1307-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-06-05
AVKARE Inc.D-1305-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-06-04
AVKARE Inc.D-1304-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-06-04
Teva Pharmaceuticals USAD-1331-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-06-02
Teva Pharmaceuticals USAD-1332-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-06-02
Amneal Pharmaceuticals of New York, LLCD-1349-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-05-29
Amneal Pharmaceuticals of New York, LLCD-1348-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-05-29
Amneal Pharmaceuticals of New York, LLCD-1351-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-05-29
Amneal Pharmaceuticals of New York, LLCD-1354-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-05-29
Amneal Pharmaceuticals of New York, LLCD-1350-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-05-29
Amneal Pharmaceuticals of New York, LLCD-1352-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-05-29
Amneal Pharmaceuticals of New York, LLCD-1353-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-05-29
Amneal Pharmaceuticals of New York, LLCD-1344-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-05-29
Amneal Pharmaceuticals of New York, LLCD-1393-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-05-29
Amneal Pharmaceuticals of New York, LLCD-1347-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-05-29
Amneal Pharmaceuticals of New York, LLCD-1343-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-05-29
Amneal Pharmaceuticals of New York, LLCD-1345-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelClass II2020-05-29
Apotex Inc.D-1303-2020CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above acceptable intake levelsClass II2020-05-27
Amneal Pharmaceuticals of New York, LLCD-1253-2020CGMP Deviations: potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA.Class II2020-04-15
Direct RxD-0017-2021CGMP Deviations: Presence of NDMA impurity detected in product.Class II2020-01-15
Direct RxD-0016-2021CGMP Deviations: Presence of NDMA impurity detected in product.Class II2020-01-15
Spectrum Laboratory ProductsD-0825-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2020-01-14
PD-Rx Pharmaceuticals, Inc.D-0826-2020CGMP Deviations: Received notice from supplier of potential -Nitrosodimethylamine (NDMA) amounts above established levels.Class II2020-01-10
Mylan Pharmaceuticals Inc.D-0791-2020CGMP Deviations: Trace amounts of an impurity, N-nitrosodimethylamine (NDMA) was detected in the API Nizatidine.Class II2020-01-07
Mylan Pharmaceuticals Inc.D-0792-2020CGMP Deviations: Trace amounts of an impurity, N-nitrosodimethylamine (NDMA) was detected in the API Nizatidine.Class II2020-01-07
Preferred Pharmaceuticals, IncD-0797-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2020-01-07
Preferred Pharmaceuticals, IncD-0796-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2020-01-07
Appco Pharma LLCD-0648-2020CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in APIClass II2020-01-07
Appco Pharma LLCD-0649-2020CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in APIClass II2020-01-07
H J Harkins Company Inc dba Pharma PacD-0793-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2020-01-06
AAA Pharmaceutical, Inc.D-0645-2020CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in APIClass II2019-12-26
AAA Pharmaceutical, Inc.D-0646-2020CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in APIClass II2019-12-26
Denton Pharma, Inc.D-0794-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-12-20
Denton Pharma, Inc.D-0795-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-12-20
Glenmark Pharmaceuticals Inc., USAD-0643-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-12-17
Glenmark Pharmaceuticals Inc., USAD-0642-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-12-17
Glenmark Pharmaceuticals Inc., USAD-0639-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-12-17
Glenmark Pharmaceuticals Inc., USAD-0644-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-12-17
Glenmark Pharmaceuticals Inc., USAD-0640-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-12-17
Glenmark Pharmaceuticals Inc., USAD-0641-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-12-17
Granules India LimitedD-0632-2020CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in APIClass II2019-12-13
RemedyRepack Inc.D-0798-2020CGMP Deviation; Received notice from supplier of potential -Nitrosodimethylamine (NDMA) amounts above established levels.Class II2019-12-11
Preferred Pharmaceuticals, IncD-0617-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-12-02
Amneal Pharmaceuticals, Inc.D-0613-2020CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in APIClass II2019-11-22
Amneal Pharmaceuticals, Inc.D-0616-2020CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in APIClass II2019-11-22
Amneal Pharmaceuticals, Inc.D-0612-2020CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in APIClass II2019-11-22
Amneal Pharmaceuticals, Inc.D-0615-2020CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in APIClass II2019-11-22
Amneal Pharmaceuticals, Inc.D-0614-2020CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in APIClass II2019-11-22
American Health PackagingD-1003-2020CGMP Deviations: Potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA.Class II2019-11-20
AVKARE Inc.D-0524-2020CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in APIClass II2019-11-14
AVKARE Inc.D-0525-2020CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in APIClass II2019-11-14
Precision Dose Inc.D-1004-2020CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API.Class II2019-11-13
AuroMedics Pharma LLCD-0529-2020CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.Class II2019-11-06
AuroMedics Pharma LLCD-0528-2020CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.Class II2019-11-06
AuroMedics Pharma LLCD-0527-2020CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.Class II2019-11-06
AuroMedics Pharma LLCD-0530-2020CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.Class II2019-11-06
AuroMedics Pharma LLCD-0526-2020CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.Class II2019-11-06
American Health PackagingD-0631-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-11-01
Novitium Pharma LLCD-0311-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-10-25
Sanofi-Aventis U.S. LLCD-0534-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-10-22
Sanofi-Aventis U.S. LLCD-0540-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-10-22
Sanofi-Aventis U.S. LLCD-0542-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-10-22
Sanofi-Aventis U.S. LLCD-0544-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-10-22
Sanofi-Aventis U.S. LLCD-0535-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-10-22
Sanofi-Aventis U.S. LLCD-0536-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-10-22
Sanofi-Aventis U.S. LLCD-0539-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-10-22
Sanofi-Aventis U.S. LLCD-0538-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-10-22
Sanofi-Aventis U.S. LLCD-0543-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-10-22
Sanofi-Aventis U.S. LLCD-0541-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-10-22
Sanofi-Aventis U.S. LLCD-0545-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-10-22
Sanofi-Aventis U.S. LLCD-0537-2020CGMP Deviations: Presence of NDMA impurity detected in product.Class II2019-10-22
Maquet Cardiovascular, LLCZ-1640-2019Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assuredClass II2019-04-18
Maquet Cardiovascular, LLCZ-1506-2019Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assuredClass II2019-04-18
Maquet Cardiovascular, LLCZ-1638-2019Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assuredClass II2019-04-18
Maquet Cardiovascular, LLCZ-1509-2019Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assuredClass II2019-04-18
Maquet Cardiovascular, LLCZ-1564-2019Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assuredClass II2019-04-18
Maquet Cardiovascular, LLCZ-1651-2019Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assuredClass II2019-04-18
Maquet Cardiovascular, LLCZ-1591-2019Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assuredClass II2019-04-18
Maquet Cardiovascular, LLCZ-1587-2019Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assuredClass II2019-04-18
Maquet Cardiovascular, LLCZ-1663-2019Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assuredClass II2019-04-18
Maquet Cardiovascular, LLCZ-1532-2019Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assuredClass II2019-04-18
Maquet Cardiovascular, LLCZ-1643-2019Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assuredClass II2019-04-18
Maquet Cardiovascular, LLCZ-1585-2019Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assuredClass II2019-04-18
Maquet Cardiovascular, LLCZ-1672-2019Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assuredClass II2019-04-18
Maquet Cardiovascular, LLCZ-1659-2019Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assuredClass II2019-04-18
Maquet Cardiovascular, LLCZ-1656-2019Custom Tubing Sets for Extracorporeal Circulation (ECC)-During sterilization, the closed stopcock/non-vented cap configuration may prevent the flow of humidity/ethylene oxide gas into the fluid-path between the closed port and the non-vented cap therefore the Sterility Assurance Level (SAL) of the stopcock ports cannot be assuredClass II2019-04-18
Ecolab IncD-1064-2019Chemical Contamination: low levels of various substituted benzene (aromatic) compounds identified in the product after complaints of malodor.Class II2019-02-06
Ecolab IncD-1062-2019Chemical Contamination: low levels of various substituted benzene (aromatic) compounds identified in the product after complaints of malodor.Class II2019-02-06
Karl Storz EndoscopyZ-1942-2020The sterile single-use tubing may contain higher ethylene oxide (EO) residues than the acceptable level.Class III2019-01-09

Literature

The newest science behind each mass tort.

The most recent published papers on the drug, product and exposure claims these experts testify about: GLP-1 drugs, hair straighteners, talc, social media and adolescents, PFAS, benzene, asbestos, ethylene oxide and air pollution. Titles and journals only.

118 papers · updated November 2, 2026 · by topic, newest first

PaperTopicJournalPublished
GLP-1 receptor agonists and ocular safety- Pharmacokinetic insights into ischemic optic neuropathy and diabetic retinopathy risk: A review.GLP-1 drugs: gastrointestinal and eye injuriesBiomolecules & biomedicine2026 Sep 7
Indication-specific adverse event profiles of semaglutide and liraglutide: a FAERS disproportionality analysis.GLP-1 drugs: gastrointestinal and eye injuriesFrontiers in pharmacology2026 Sep 29
[Non-arteritic anterior ischemic optic neuropathy associated with tirzepatide (Mounjaro®): A case report documented by multimodal imaging].GLP-1 drugs: gastrointestinal and eye injuriesJournal francais d'ophtalmologie2026 Sep 29
Non-Arteritic Anterior Ischaemic Optic Neuropathy Associated with Semaglutide use.GLP-1 drugs: gastrointestinal and eye injuriesIrish medical journal2026 Sep 28
Gastrointestinal Symptom Events and Motility Alterations Associated With GLP-1 Receptor Agonists.GLP-1 drugs: gastrointestinal and eye injuriesNeurogastroenterology and motility2026 Oct
GLP-1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications.GLP-1 drugs: gastrointestinal and eye injuriesJournal of internal medicine2026 Oct 9
Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS.GLP-1 drugs: gastrointestinal and eye injuriesEndocrine2026 Oct 29
Decoding the Safety Profile of GLP-1 Receptor Agonists: Facts, Myths, and Ongoing Controversies.GLP-1 drugs: gastrointestinal and eye injuriesCurrent obesity reports2026 Oct 21
Diabetic Retinal Disease Onset and Progression During Established Semaglutide or Tirzepatide Treatment: A Retrospective Comparative Cohort Study With a Descriptive Regional Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Review.GLP-1 drugs: gastrointestinal and eye injuriesCureus2026 Oct 19
Semaglutide Use and Risk of Diabetic Retinopathy and Non-Arteritic Anterior Ischemic Optic Neuropathy in Type 2 Diabetes: A Single-Center Retrospective Cohort Study.GLP-1 drugs: gastrointestinal and eye injuriesClinical ophthalmology (Auckland, N.Z.)2026 Oct 12
Optimal Timing of GLP-1 Receptor Agonist Initiation in Patients with Obesity Eligible for Metabolic Bariatric Surgery.GLP-1 drugs: gastrointestinal and eye injuriesObesity surgery2026 Jul 18
Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m(2): A Target Trial Emulation.GLP-1 drugs: gastrointestinal and eye injuriesDiabetes, obesity & metabolism2026 Aug 25
Integrating epidemiology and mechanistic studies links PFAS exposure to ocular diseases and implicates PFOS-associated glaucoma risk through the PI3K/Akt-MMP3 axis.PFAS exposureFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association2026 Sep 30
Multilevel meta-regression analysis of per- and polyfluoroalkyl substances toxicity to aquatic macrophytes.PFAS exposureAquatic toxicology (Amsterdam, Netherlands)2026 Sep 28
Climate change meets emerging contaminants: salinity shapes PFAS toxicity in Mytilus galloprovincialis.PFAS exposureAquatic toxicology (Amsterdam, Netherlands)2026 Sep 25
Association between mixed per- and polyfluoroalkyl substance exposure and thyroid hormone levels in the general population of Shandong, China.PFAS exposureFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association2026 Sep 23
Joint effects of per- and polyfluoroalkyl substances and heavy metals on dyslipidemia: Integrated epidemiological and bioinformatics analysis.PFAS exposureEnvironmental pollution (Barking, Essex : 1987)2026 Sep 22
Dietary exposure to per- and polyfluoroalkyl substances among the general population in Jinan, Shandong Province, China: An integrated approach combining deterministic assessment, probabilistic assessment, and the toxicological priority index.PFAS exposureEnvironmental pollution (Barking, Essex : 1987)2026 Sep 18
Microplastic co-exposure increases PFAS bioaccumulation without universally amplifying toxicity in aquatic organisms: A multi-endpoint meta-analysis.PFAS exposureAquatic toxicology (Amsterdam, Netherlands)2026 Sep 15
Salinity-driven partitioning of structurally distinct PFAS and implications for ecological risk in urbanized estuaries.PFAS exposureEnvironmental pollution (Barking, Essex : 1987)2026 Sep 15
Embryonic exposure to ambient concentrations of PFAS impairs the innate immune response in zebrafish and fathead minnow.PFAS exposureJournal of immunotoxicology2026 Sep 10
The transfer of per- and polyfluoroalkyl substances (PFAS) from mother to child: Comparison between maternal and cord blood in an Italian cohort.PFAS exposureJournal of pharmaceutical and biomedical analysis2026 Jun 30
Targeted and Non-Targeted Analysis of Novel and Legacy Per and Polyfluoroalkyl Substances in River Water by Direct Analysis in Real Time Mass Spectrometry.PFAS exposureRapid communications in mass spectrometry : RCM2026 Dec 30
A simple and sensitive QuEChERS-based LC-MS/MS method for quantifying 30 per- and polyfluoroalkyl substances (PFAS) in human serum: application to firefighter biomonitoring.PFAS exposureTalanta2026 Aug 5
Endothelial function in relation to low-level chronic residential air pollution in a general population: a cohort study.air pollution and healthBlood pressure2026 Sep 9
Breathing in harm: current insights into the effects of air pollution on cardiorespiratory health.air pollution and healthMedical gas research2026 Sep 12
Long-term exposure to ambient air pollution and circulating white blood cell homeostasis among adults in China: Time-window-specific associations and the mediating role of fasting blood glucose.air pollution and healthEnvironmental pollution (Barking, Essex : 1987)2026 Sep 10
Associations between air pollution and pediatric asthma hospitalizations across vulnerable groups in Louisiana.air pollution and healthEnvironmental epidemiology (Philadelphia, Pa.)2026 Oct 26
Role of neighborhood vulnerability and opportunity in the association between prenatal air pollution and autism-related traits in the ECHO Cohort.air pollution and healthEnvironmental research2026 Oct 1
Residents' perspectives on a community health worker-delivered household air pollution prevention programme pilot in Eldoret, Kenya: a qualitative evaluation.air pollution and healthGlobal health action2026 Mar 9
Effects of short-term exposure to air pollution on respiratory symptoms and lung function among patients with asthma.air pollution and healthMedical gas research2026 Mar 6
Air pollution and adverse birth outcomes: a narrative review of epidemiological and mechanistic findings.air pollution and healthJournal of environmental health science & engineering2026 Jun 26
Effect of air pollution on determination of threshold temperatures for heat and cold waves in Spain.air pollution and healthEnvironmental pollution (Barking, Essex : 1987)2026 Aug 28
Air Pollution and Climate Regulate the Large-Scale Pattern of Foliar Nitrogen Uptake by Urban Street Trees.air pollution and healthPlant, cell & environment2026 Aug 25
Household and occupational air pollution, and demographic drivers of COPD: a hospital-based cross-sectional study in a high-pollution urban setting.air pollution and healthJournal of environmental health science & engineering2026 Aug 19
Impacts of air pollution on postoperative renal injuries: evidence from a multicenter cohort study of 112, 643 patients.air pollution and healthAnnals of medicine2026 Apr 9
Environmental Asbestos Exposure as a Possible Pathway to Early-Onset Pleural Mesothelioma: A Case From Afghanistan and Pakistan to London.asbestosRespirology case reports2026 Sep 30
The geographic legacy of asbestos exposure: Spatiotemporal patterns of pleural cancer mortality in Spain, 1999-2023.asbestosCancer epidemiology2026 Sep 1
Invisible threats: environmental asbestos exposure and water contamination in a former mining area of Northeastern Brazil.asbestosCadernos de saude publica2026 Sep 18
Exogenous antioxidant and antigenotoxic agents against asbestos-induced toxicity: A systematic review with implications for post-earthquake exposure scenarios.asbestosEnvironmental toxicology and pharmacology2026 Sep 14
When art anticipates disease: asbestos, conceptual painting and mesothelioma.asbestosMedical humanities2026 Oct 20
Banned here, sold elsewhere: globalization, e-commerce and the continuing circulation of asbestos-containing products.asbestosEnvironmental health : a global access science source2026 Oct 14
Who participates in LDCT screening for the early detection of lung cancer after long-term occupational exposure to asbestos dust? Results of the analysis of administrative and medical routine data from the German Social Accident Insurance.asbestosBMC pulmonary medicine2026 Oct 12
Temporal Trends in Mortality and Disability from Occupational Asbestos Exposure in Southeast Asia, 1990-2023.asbestosJournal of occupational and environmental medicine2026 May 29
Evaluation of exposure to asbestos from the cutting of cement pipe with a powered saw.asbestosInhalation toxicology2026 Jul 12
Environmental asbestos exposure and lung cancer burden compared with mesothelioma in rural Türkiye: A 33-Year population-based cohort study.asbestosLung cancer (Amsterdam, Netherlands)2026 Aug 26
Occupational asbestos exposure and lung cancer: contemporary research trends, exploratory genetic evidence, and global burden from 1990 to 2021.asbestosJournal of thoracic disease2026 Aug 21
ADRB2 modulates asbestos-induced pleural mesothelioma progression by influencing IL-17/NF-κB-related inflammatory signalling: An integrated network toxicology, multi-omics and experimental study.asbestosChemico-biological interactions2026 Aug 13
Long-term ambient benzene exposure increases incident NAFLD risk through accelerated biological aging.benzene exposureiScience2026 Sep 30
Advances in biomarkers of benzene exposure and toxicity: From mechanistic insights to occupational health applications (Review).benzene exposureMolecular medicine reports2026 Sep 25
Benzene and cigarette smoke co-exposure exacerbates hematotoxicity involving the AhR-NLRP3 signaling pathway.benzene exposureToxicology reports2026 Oct 22
Benzene metabolite catechol promotes microglia-mediated neuroinflammation in Alzheimer's disease via regulating NF-κB signaling.benzene exposureEcotoxicology and environmental safety2026 Oct 21
The maternal-placental-fetal liver axis: A mechanistic framework for understanding benzene developmental hematotoxicity.benzene exposureReproductive toxicology (Elmsford, N.Y.)2026 Oct 19
Development and application of a prediction system for benzene series emission concentration and inhalation exposure risk of children's toys.benzene exposureAnalytical methods : advancing methods and applications2026 Oct 19
Identification of predisposing factors for hematotoxicity in occupational benzene-exposed workers using machine learning and SHAP interpretation.benzene exposureToxicology letters2026 Oct 15
Exposure assessment of benzene, toluene, and xylene in petrol station attendants: methods, biomarkers, and the case for integrated monitoring: a narrative review.benzene exposureFrontiers in public health2026 Oct 14
Associations of cumulative occupational benzene exposure with genotoxic and immunosenescence-related biomarkers: a cross-sectional study.benzene exposureFrontiers in public health2026 Oct 14
Comparison of effects of charcoal versus electric heating of waterpipe tobacco on carbon monoxide levels: Cardiovascular measures; benzene, pyrene, and nicotine uptake; and subjective reactions.benzene exposureToxicology reports2026 Jun 25
Benzene metabolite-targeted gene ATF7IP2 drives glutamate metabolic reprogramming to promote acute myeloid leukemia initiation.benzene exposureToxicology letters2026 Aug 22
PRMT5 lactylation mediates SIRT6-dependent DNA damage and senescence in benzene-induced hematotoxicity.benzene exposureFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association2026 Aug 18
Extraterritorial Environmental Accountability of AI Data Centers via Transboundary Harm and Due-Diligence Norms.data centers: energy, water, emissionsEnvironmental management2026 Sep 15
Data centre expansion and water insecurity in low- and middle income countries.data centers: energy, water, emissionsTropical doctor2026 Sep 14
One Quarter of Global Data Centers are Located in Water-Stressed Areas.data centers: energy, water, emissionsEnvironmental science & technology2026 Oct 6
Data centers and Artificial Intelligence: a double threat to worldwide sustainability and a worsening of the recently declared "water bankruptcy".data centers: energy, water, emissionsAnais da Academia Brasileira de Ciencias2026 Oct 23
Thermal analysis of ternary hybrid nanofluids for advanced cooling of AI chips and data centers using dual numerical techniques.data centers: energy, water, emissionsDiscover nano2026 Oct 23
Flexible data centers reduce power system costs but can increase emissions.data centers: energy, water, emissionsiScience2026 Jun 26
Multi-Objective Optimization for Data Center HVAC Systems Based on Edge-Cloud Collaborative Deep Reinforcement Learning.data centers: energy, water, emissionsSensors (Basel, Switzerland)2026 Aug 7
Energy, Exergy, Economic, Environment Analysis and Multiobjective Optimization of the Organic Rankine Cycle Integrating an Absorption Heat Transformer Driven by Geothermal Energy for Data Center Power Supply and Waste Heat Recovery.data centers: energy, water, emissionsACS omega2026 Aug 25
Pursuing a hierarchical taxonomy in a water-cooled data center room.data centers: energy, water, emissionsScientific reports2026 Aug 24
From Gigabytes to Gigatons: China's Data Centers and Their Carbon Footprint from 2006 to 2050.data centers: energy, water, emissionsEnvironmental science & technology2026 Aug 18
System-scale design and analysis of desalination systems for meeting water needs of data centers.data centers: energy, water, emissionsWater research2026 Aug 17
How sovereign control, decarbonization and energy costs shape public support for data centers.data centers: energy, water, emissionsNature communications2026 Aug 10
Regarding ethylene exposure and endogenous ethylene oxide levels in humans (Lin et al., 2025).ethylene oxideJournal of exposure science & environmental epidemiology2026 Sep 5
Rheological dataset of calcium-alginate hydrogels after ultraviolet, ethylene oxide, steam, gamma, and high hydrostatic pressure treatments.ethylene oxideData in brief2026 Oct 13
Sensitive Quantification of the Ethylene Oxide Hemoglobin Adduct N-(2-Hydroxyethyl)-l-valine from Minimal Blood Volumes.ethylene oxideChemical research in toxicology2026 May 23
How to identify the healthy worker survivor effect empirically and how to interpret results from published studies: the NIOSH ethylene oxide cohort as a case study.ethylene oxideAmerican journal of epidemiology2026 Mar 9
US EPA proposes easing ethylene oxide emission standards.ethylene oxideThe Lancet. Oncology2026 Mar 19
Investigation of Ethylene Oxide Genotoxicity Dose-Response to Inform Cancer Risk Assessment.ethylene oxideEnvironmental and molecular mutagenesis2026 Jun
Effects of Ethylene Oxide Sterilisation on the In Vitro Antimicrobial Activity of Preformulated Antibiotic-Impregnated Calcium Sulfate Beads.ethylene oxideVeterinary and comparative orthopaedics and traumatology : V.C.O.T2026 Jun 17
Molecular dosimetry of hemoglobin adducts in mice exposed to ethylene oxide.ethylene oxideArchives of toxicology2026 Jul 1
Molecular dosimetry of DNA adducts in mice exposed to ethylene oxide.ethylene oxideToxicological sciences : an official journal of the Society of Toxicology2026 Jul 1
Engineering of green sterilization technology to obtain biocompatible aerogels: Supercritical CO(2) versus ethylene oxide and gamma radiation.ethylene oxideBiomaterials advances2026 Jan 2
A risk assessment of ethylene oxide release from a sterilization facility into a community.ethylene oxideJournal of the Air & Waste Management Association (1995)2026 Apr 30
Use of hair relaxers and hair dyes during pregnancy and breast tissue composition in mothers and adolescent daughters.hair straighteners and cancerBreast cancer research : BCR2026 Jul 29
Use of hair straighteners and chemical relaxers and incidence of non-reproductive cancers.hair straighteners and cancerJournal of the National Cancer Institute2026 Jan 1
Systematic Review of the Epidemiology of Hair Relaxer Use and Hormone-Sensitive Reproductive Outcomes Among Black Adult Women in the United States.hair straighteners and cancerJournal of applied toxicology : JAT2025 Jan 19
A systematic review of association between use of hair products and benign and malignant gynecological conditions.hair straighteners and cancerEuropean journal of obstetrics, gynecology, and reproductive biology2024 Feb 14
Hair relaxer use and risk of uterine cancer in the Black Women's Health Study.hair straighteners and cancerEnvironmental research2023 Oct 10
Dispelling myths of chemical hair relaxers causing uterine cancer.hair straighteners and cancerJournal of the American Academy of Dermatology2023 Jun 24
And It'll Come Back Real Baby Fine: Black Women's Experiences With Hair Loss and Regrowth After Chemotherapy for Breast Cancer Treatment.hair straighteners and cancerQualitative health research2022 May 26
Relation of circulating estrogens with hair relaxer and skin lightener use among postmenopausal women in Ghana.hair straighteners and cancerJournal of exposure science & environmental epidemiology2022 Jan 6
Chemical Relaxers and Hair-Straightening Products: Potential Targets for Hormone-Related Cancer Prevention and Control.hair straighteners and cancerJournal of the National Cancer Institute2022 Dec 8
Hair product use and breast cancer incidence in the Black Women's Health Study.hair straighteners and cancerCarcinogenesis2021 Jul 16
Associations of hair dye and relaxer use with breast tumor clinicopathologic features: Findings from the Women's circle of Health Study.hair straighteners and cancerEnvironmental research2021 Aug 11
"This didn't exist back then": A focus group study on adolescents' account of mental illness perceptions in the context of family, peers, and social media.social media and adolescent mental healthSocial science & medicine (1982)2026 Sep 4
Associated Factors of Problematic Social Media Use, Cyberbullying, and Cybervictimization Among Adolescents: A Cross-Sectional Study.social media and adolescent mental healthJournal of child and adolescent psychiatric nursing : official publication of the Association of Child and Adolescent Psychiatric Nurses, Inc2026 Nov
Problematic Social Media Use and Depressive and Anxiety Symptoms in Adolescents.social media and adolescent mental healthPediatrics2026 Nov 1
"With all your friends in your pocket" - a qualitative study about adolescents' experiences with social media from a health-promoting perspective.social media and adolescent mental healthInternational journal of qualitative studies on health and well-being2026 Mar 6
Mapping mental health and suicide-related discourse on TikTok: An AI-based social media listening study.social media and adolescent mental healthJournal of affective disorders2026 Jun 15
Problematic Social Media Use Trajectories Are Linked With Lower Cognitive Performance in Adolescents.social media and adolescent mental healthAmerican journal of preventive medicine2026 Jul 15
Problematic social media use in adolescents: Latent profile analysis and associations with mental health outcomes.social media and adolescent mental healthJournal of affective disorders2026 Jul 14
Review: Social media use and adolescent mental health - an umbrella review and power analysis.social media and adolescent mental healthChild and adolescent mental health2026 Jan 27
Impact of Social Media on Adolescents and Young Adults with Solid Tumors or Hematological Malignancies: A Multicenter Study.social media and adolescent mental healthJournal of adolescent and young adult oncology2026 Feb 27
Sexual and gender identity differences in mental health concerns as a function of social media use and cyberbullying among U.S. youth.social media and adolescent mental healthJournal of research on adolescence : the official journal of the Society for Research on Adolescence2026 Dec
Behind the screen: Social media use and internalizing problems in adolescents.social media and adolescent mental healthJournal of affective disorders2026 Aug 3
Baseline emotional distress predicts psychological response to a social media reduction intervention in distressed youth: a precision mental health approach.social media and adolescent mental healthJournal of affective disorders2026 Aug 26
Talc Use and Risk of Cancer: An Umbrella Review and Overlapped Analysis.talc and cancerCancer reports (Hoboken, N.J.)2026 Oct
Personal Talc Use and Incident Lung Cancer.talc and cancerCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2026 Nov 2
Safety and Efficacy of Single-Stage Synchronous Bilateral VATS Talc Poudrage for Malignant Pleural Effusion.talc and cancerCancers2026 May 22
Talc Exposure and Risk of Ovarian Cancer: A Systematic Review and Meta-Analysis with Limited Evidence on Cervical and Endometrial Cancers.talc and cancerCancers2026 May 13
Development and validation of a predictive model for pleural effusion control following talc pleurodesis in malignant pleural effusion.talc and cancerInternational journal of clinical oncology2026 Mar 17
The NTP chronic inhalation study does not support an inherent lung cancer hazard of talc: Implications of lung particle overload and maximum tolerated dose.talc and cancerRegulatory toxicology and pharmacology : RTP2026 Jun 29
Combined indwelling pleural catheter with thoracoscopic talc poudrage for malignant pleural effusion management: a randomized non-inferiority trial.talc and cancerBMC pulmonary medicine2026 Jul 4
Interpretation of the IARC quantitative bias analysis of talc and ovarian cancer.talc and cancerGlobal epidemiology2026 Jan 21
Comment on Roberts at al: Historical cosmetic talc consumption and incidence of mesothelioma in the United States. International Journal of Environmental Health Research, 35:4, 972-980.talc and cancerInternational journal of environmental health research2026 Jan 20
Do People Occupationally Exposed to Asbestos-Free Talc Have Elevated Risk for Lung Cancer, Laryngeal Cancer, or Mesothelioma?talc and cancerJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2026 Aug
Predictors of pleurodesis success after combined outpatient thoracoscopic talc poudrage and tunneled indwelling pleural catheter placement.talc and cancerJournal of thoracic disease2026 Aug 31
Occupational Exposure to Asbestos-Free Talc and Risk of Respiratory Cancers, Including Larynx, Lung, and Mesothelioma: A Systematic Review and Meta-Analysis.talc and cancerJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2026 Apr 10

In the knowledge graph

Where Expert Litigation Intelligence meets the others.

Each row is a shared issue, agency, place or firm. The numbers count the evidenced connections each capability makes to it, so you can see how a finding here carries into the next capability.

Shared entityExpert LitigationLaw FirmGovernment BuyingProject ApprovalLocal Development
Hazardous substances & cleanup Issue1154860600
Air quality & emissions Issue451251144342
Health care Issue93510957302
Data centers Issue1296740213
PFAS Issue4475862·
Artificial intelligence Issue2257533·
Data privacy Issue1311641·
Autonomous vehicles & drones Issue13329·
Finance, securities & capital markets Issue20260·15·
Toxic exposure Issue2114·3·
Virginia Place1·76·21
Energy & climate Issue127·21·

See it answer

A real question, answered by Expert Litigation Intelligence.

Tools

  • search_expertsExperts named in published opinions, filtered by field, court and ruling.
  • get_expertA full dossier: every naming sentence, Rule 702 outcomes, exhibits, cross-exam outline.
  • list_filtersValid fields, courts and ruling values, with counts.
  • database_statsCoverage and the inclusion rule, so claims about completeness are exact.

A request

“Which environmental experts have testified about asbestos, and how did courts rule?”

Lookup

search_experts(query: "asbestos", industry: "environmental", limit: 3)

2 experts matched

Hands forward toLaw Firm Intelligence: The field of the dispute, so counsel with matching evidence can be found.

Real results from the live data.

Works with

Better with the other capabilities.

Receives from

Hands forward to

Get started

Start with one capability. Connect the rest when you need them.

Use a capability on its own, or connect all five so every answer starts from what the others found. Your team works in the site; your AI agents reach the same capabilities over MCP.